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incidence
Cancer of the nasopharynx (NPC) is rare in Europe, with an
annual crude incidence rate of 1.1 per 100 000. On the
European scale, NPC accounts for 4760 new cases per year.
Incidence is higher in men than women. [1, 2].
In Europe, the relative survival for NPC was 76% at 1 year
and 50% at 5 years in adults. There were no survival
differences between the sexes. The effect of age on survival is
marked. Survival at 5 years was 72% for the youngest age
group (15–45 years) and 36% in the oldest group of patients
(65–74 years) [1, 2].
diagnosis
Deﬁnitive diagnosis is made by endoscopic-guided biopsy of
the primary nasopharyngeal tumor. The histological type
should be classiﬁed according to World Health Organization
(WHO) classiﬁcation [3]. Since the ﬁrst disease sign in
patients is often the appearance of neck nodes it is not
infrequent that patients undergo neck biopsy and/or neck
nodal dissection. This procedure is not recommended since
it may reduce cure probability and have an impact on late
treatment sequelae.
staging and risk assessment
NPC is clinically staged according to the International
Union Against Cancer (UICC) and American Joint
Committee on Cancer (AJCC) staging system (Table 1).
Routine staging procedures include history, physical
examination including cranial nerve examination, complete
blood cell count, serum biochemistry (including liver
function test), chest X-ray, nasopharyngoscopy, computed
tomography (CT) scan or magnetic resonance imaging
(MRI) of nasopharynx and base of skull and neck. Although
MRI is generally preferred if available, each center will
choose the best imaging technique according to their usual
clinical practice and experience [III, B]. Imaging for distant
metastases including isotope bone scan and CT scan of
chest and upper abdomen could be considered for at-risk
subsets (node positive, especially N3 stage) and for those
patients with clinical or biochemical abnormalities detected
[III, B]. The use of positron emission tomography CT scan
can replace the traditional work-up for detection of distant
metastatic disease since it has proved to be the most
sensitive, speciﬁc and accurate diagnostic method. Both the
pre-treatment and post-treatment plasma/serum load of
Epstein-Barr viral DNA has been shown to be of prognostic
value [III, B] [4–8].
treatment
The optimal treatment strategy of patients with advanced NPC
should be discussed in a multidisciplinary team. Radiation
therapy (RT) is the mainstay of treatment and is an essential
component of curative-intent treatment of non-disseminated
NPC. Stage I disease is treated by RT alone, while stage III,
IVA, IVB disease are treated by RT with concurrent
chemotherapy [I, A]. Concurrent chemotherapy is
recommended for stage II disease [I, B] [9]. Patients should be
treated by intensity-modulated radiation therapy (IMRT) [II,
A] [10]. RT is targeted to the primary tumor and the adjacent
regions considered at risk of microscopic spread from the
tumor, and to both the sides of the neck (levels Ib–V, and
retropharyngeal nodes). For patients with lower neck nodes,
the supraclavicular fossa should be included as well. Elective
nodal irradiation is recommended for N0 stage disease. The
consensus is that a total dose of 70 Gy is needed for
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eradication of gross tumor and either 50–60 Gy or 46–60 Gy
for elective treatment of potential risk sites. To minimize the
risk of late toxicity (particularly, to adjacent neurological
structures), fractional dose >2 Gy per daily fraction and
excessive acceleration with multiple fractions >1.9 Gy/fraction
should be avoided [III, E]. IMRT may offer improvement in
local tumor control [II, A], and reduction in radiation
xerostomia in early-stage disease [II, A]. The standard agent
used in concurrent chemotherapy–RT is cisplatin [I, A]. This
provides a beneﬁt in terms of overall survival and on both
locoregional and distant control [9, 11–15]. While three cycles
of adjuvant cisplatin-5FU has been a standard part of many
concurrent chemoradiotherapy regimens, its beneﬁt is
uncertain and toxic effect is substantial [16]. Cisplatinum-
based induction chemotherapy has been shown to improve
disease-free survival and may be considered in locally
advanced disease although it is not seen as a standard
treatment [II, B] [17]. In no case should induction
chemotherapy negatively affect the optimal administration of
concomitant chemoradiation.
follow-up
Documentation of complete remission in the nasopharynx and
neck through clinical and endoscopic examination and/or
imaging studies is important. MRI is often used to evaluate the
response to RT or chemoradiotherapy, especially for T3 and T4
tumors, though distinction between post-irradiation changes
and recurrent tumors may be difﬁcult. Follow-up for patients
includes periodic examination of the nasopharynx and neck,
cranial nerve function and evaluation of systemic complaints to
identify distant metastasis. For T3 and T4 tumors, MRI might
be used on a 6- to 12-month basis to evaluate the nasopharynx
and the base of the skull at least for the ﬁrst few years after
treatment. Evaluation of thyroid function in patients with
irradiation to the neck is recommended at 1, 2 and 5 years.
Table 1. The International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system for NPC, seventh edition
(2010)
Primary tumor (T)
T1 Tumor conﬁned to the nasopharynx, or extends to oropharynx and/or nasal cavity
without parapharyngeal extension
T2 Tumor with parapharyngeal extension
T3 Tumor involves bony structures of skull base and/or paranasal sinuses
T4 Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit,
or with extension to the infratemporal fossa/masticator space
Regional lymph nodes (N)
N1 Unilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension,
above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal
lymph nodes, ≤6 cm, in greatest dimension
N2 Bilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension,
above the supraclavicular fossa
N3 Metastasis in a lymph node(s) >6 cm and/or to supraclavicular fossa
N3a >6 cm in dimension
N3b Extension to the supraclavicular fossa
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Anatomic stage/prognostic groups
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T1 N1 M0
T2 N0 M0
T2 N1 M0





Stage IVA T4 N0 M0
T4 N1 M0
T4 N2 M0
Stage IVB Any T N3 M0
Stage IVC Any T Any N M1
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treatment of recurrent or metastatic
disease
Small local recurrences are potentially curable and the main
issue is the choice of the most appropriate therapeutic options,
which include nasopharyngectomy, brachytherapy,
radiosurgery, stereotactic RT, IMRT or a combination of
surgery and RT, with or without concurrent chemotherapy.
Treatment decisions are tailored to the speciﬁc situation of
individual cases, taking into consideration the volume, location
and extent of the recurrent tumor [III, A]. Regional recurrence
is managed by radical neck dissection if resectable [III, A].
In metastatic NPC, palliative chemotherapy should be
considered for patients with adequate performance status.
Platinum combination regimens are commonly used as ﬁrst-
line therapy since cisplatin represents the most effective drug.
Other active agents include paclitaxel, docetaxel, gemcitabine,
capecitabine, irinotecan, vinorelbine, ifosfamide, doxorubicin
and oxaliplatin, which can be used as single agents or in
combination [III, B]. Polychemotherapy is more active than
monotherapy. In this context treatment choice should be based
on previous treatments and the expected toxicity [18].
notes
Levels of evidence [I–V] and grades of recommendation [A–E]
adapted from the Infectious Diseases Society of American-
United States Public Health Service Grading System are given
in square brackets. Statements without grading were considered
justiﬁed standard clinical practice by the experts.
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Table 2 Summary of treatment recommendations for Cancer of the
nasopharynx (NPC)
Early stage Stage I Radiation alone
Intermediate stage Stage II Concurrent chemoradiotherapy
(I, B)
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